Literature DB >> 16859585

Prostate adenocarcinoma and human immunodeficiency virus: report of three cases and review of the literature.

John K O'Connor1, Lucien A Nedzi, Ellen L Zakris.   

Abstract

The objective of this study was to evaluate the acute tolerance to definitive external-beam radiation therapy (RT; EBRT) in patients with prostate adenocarcinoma and HIV and to review the published literature for this population. Three patients with prostate adenocarcinoma and HIV were treated with definitive RT. Medical records were reviewed for prostate cancer and HIV characteristics, RT details, and acute toxicity. A review of the published literature was performed for epidemiology, management, and outcome of these patients. All 3 patients had excellent acute tolerance to definitive EBRT and, with short follow-up, all had decreasing prostate-specific antigen levels. The published literature regarding patients with prostate adenocarcinoma and HIV is scarce but suggests that men with HIV might be at higher risk of developing prostate cancer. External-beam radiation therapy, brachytherapy, and surgery have all been used in the management of these patients. All 3 patients with prostate adenocarcinoma and HIV had an excellent acute tolerance to EBRT. Prostate cancer is expected to become an increasingly important health problem for men infected with HIV as their life expectancy lengthens.

Entities:  

Mesh:

Year:  2006        PMID: 16859585     DOI: 10.3816/CGC.2006.n.023

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  7 in total

1.  Are HIV-infected men vulnerable to prostate cancer treatment disparities?

Authors:  Adam B Murphy; Ramona Bhatia; Iman K Martin; David A Klein; Courtney M P Hollowell; Yaw Nyame; Elodi Dielubanza; Chad Achenbach; Rick A Kittles
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-25       Impact factor: 4.254

2.  Clinical presentation and outcomes of prostate cancer in an urban cohort of predominantly African American, human immunodeficiency virus-infected patients.

Authors:  David J Riedel; Eric R Cox; Kristen A Stafford; Bruce L Gilliam
Journal:  Urology       Date:  2014-11-04       Impact factor: 2.649

Review 3.  Management of prostate cancer in HIV-positive patients.

Authors:  Matthew S Wosnitzer; Franklin C Lowe
Journal:  Nat Rev Urol       Date:  2010-04-27       Impact factor: 14.432

Review 4.  Radiotherapy for patients with the human immunodeficiency virus: are special precautions necessary?

Authors:  Nadine Housri; Robert Yarchoan; Aradhana Kaushal
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

Review 5.  Evolving spectrum and incidence of non-AIDS-defining malignancies.

Authors:  Liron Pantanowitz; Bruce J Dezube
Journal:  Curr Opin HIV AIDS       Date:  2009-01       Impact factor: 4.283

6.  Clinical characteristics and outcomes of HIV-seropositive men treated with surgery for prostate cancer.

Authors:  Sudeh Izadmehr; Michael Leapman; Adele R Hobbs; Maria Katsigeorgis; Fatima Nabizada-Pace; Seyed Behzad Jazayeri; David B Samadi
Journal:  Int Urol Nephrol       Date:  2016-06-18       Impact factor: 2.370

Review 7.  Is There an Optimal Curative Option in HIV-Positive Men with Localized Prostate Cancer? A Systematic Review.

Authors:  John Baladakis; Marlon Perera; Damien Bolton; Nathan Lawrentschuk; Ahmed Adam
Journal:  Curr Urol       Date:  2019-07-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.